A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease

Tuesday, January 25th, 2022

This Phase I, single-dose, open-label imaging study evaluated pulmonary, extrathoracic, and regional lung deposition patterns with radiolabeled budesonide/glycopyrrolate/formoterol fumarate delivered using a single MDI in 18 patients with moderate-to-very severe COPD. As part of the study, the Vitalograph AIM was used to confirm that included patients could correctly use the MDI device, including staying within the targeted inspiratory flow rate range for the MDI.